TIE1 (tyrosine kinase with immunoglobulin-like and EGF-like domains 1)

2012-03-01   Pipsa Saharinen  

Molecular Cancer Biology Program, Research Programs Unit, Biomedicum Helsinki, Haartmaninkatu 8, P O B 63, FIN-00014 University of Helsinki, Finland

Identity

HGNC
LOCATION
1p34.2
LOCUSID
ALIAS
JTK14,TIE
FUSION GENES

DNA/RNA

Atlas Image
The genomic (top) and the protein domain structures (below) of human TIE1. Black boxes represent exons with intervening intron sequences (lines), light gray boxes represent non-coding sequences of first and last exons. Exon length (black text) and intron length of the longest introns (pink) are indicated in nucleotides. The protein domain coding regions of exons are indicated with colours according to the TIE1 protein domain structure. SS= signal sequence, Ig= immunoglobulin-like domain, EGF= epidermal growth factor-like domain, FN3= fibronectin type-III domain, TM= transmembrane domain, TK= tyrosine kinase domain. Protein domain prediction was performed using (SMART). The crystal structure for Tie2 shows the existence of a third Ig-like domain, immediately after the SS (Barton et al., 2006), and homology modeling of Tie1 predicts a similar fold (Seegar et al., 2010).

Description

The human TIE1 gene spans 22115 bp, encoding for 23 exons in forward strand.

Transcription

Longest mRNA contains 3882 bp. Alternatively spliced forms have been reported, including transcript variant 5 (EU826590.1) coding for a soluble TIE1 ectodomain (Jin et al., 2008).

Proteins

Note

See figure above.

Description

Human TIE1 contains 1138 aa. It belongs to the protein kinase superfamily, protein receptor tyrosine kinase family, TIE subfamily. It contains 3 Ig (immunoglobulin)-like domains (I set type), 3 EGF (epidermal growth factor)-like domains, 3 fibronectin type-III domains, a single transmembrane domain and 1 intracellular split tyrosine kinase domain (Partanen et al., 1992).

Expression

TIE1 is almost exclusively expressed in endothelial cells both in human and in mouse. High expression of TIE1 mRNA is found in adult lung, heart, and placenta, some expression in kidney, whereas muscle, brain, liver and pancreas contain less TIE1 mRNA. Tie1 mRNA is present widely in fetal tissues starting at embryonic day 8,5 (Korhonen et al., 1992). Tie1 mRNA is detected in differentiating angioblasts of the head mesenchyme, in the splanchnopleure and dorsal aorta as well as in migrating endothelial cells of the developing heart, in the heart endocardium and in the endothelial cells forming the lung vasculature (Korhonen et al., 1992).
TIE1 is also expressed on cultured endothelial cells, some haemopoietic progenitor cells, some myeloid leukemia cell lines having erythroid and megakaryoblastoid characteristics (Batard et al., 1996) and in adult acute myelogenous leukemia (Kivivuori et al., 2007). TIE1 expression is increased in angiogenic endothelial cells during wound-healing, in proliferating ovarial capillaries during hormone-induced superovulation and in tumor blood vessels (Korhonen et al., 1992; Kaipainen et al., 1994). Tie1 is downregulated in endothelial cells by shear stress (Chen-Konak et al., 2003), but specifically induced in the mouse vasculature by disturbed flow in vascular bifurcations and branching points along the arteries (Porat et al., 2004).
TIE1 along with ANGPT2 and TEK mRNAs were strongly expressed in cells of Kaposis sarcoma tumor cells, and cutaneous angiosarcomas, in contrast to the focal low-level expression in normal skin biopsies (Brown et al., 2000).

Localisation

Cell membrane.

Function

Studies of Tie1 gene targeted mice have revealed that Tie1 is critical for the development of blood (Puri et al., 1995) and lymphatic vasculatures (DAmico et al., 2010; Qu et al., 2010) after midgestation. Tie1 is essential for endothelial cell survival in the developing microvasculature undergoing angiogenic sprouting, and essentially in all blood vessels in adult (Partanen et al., 1996). Tie1-/- embryos die around embryonic day 13,5, depending on the background (Puri et al., 1995; DAmico et al., 2010). The Tie1 deficient or hypomorphic embryos show also signs of edema, due to lymphatic defects involving abnormally patterned lymph sacs and peripheral lymphatic vessels (DAmico et al., 2010; Qu et al., 2010).
The molecular function of TIE1 is not completely understood, as it does not directly bind the angiopoietin growth factors, which are the ligands for TEK (TIE2). However, TIE1 tyrosine phosphorylation is induced by angiopoietin-1 (Saharinen et al., 2005; Yuan et al., 2007), most likely in a complex with TEK (Marron et al., 2000; Saharinen et al., 2005). Angiopoietins activate TEK in a unique manner, which involves the translocation of TEK to endothelial cell-cell contacts, and TIE1 is also present in these complexes (Saharinen et al., 2008). Activation of the TIE1 kinase activity using chimeric TIE1 receptors was found to result in the activation of the Akt pathway (Kontos et al., 2002). The TIE1 ectodomain is proteolytically cleaved, and the cleavage is enhanced by PMA, VEGF and TNF-α (Yabkowitz et al., 1999). The proteolytic processing of TIE1 may regulate TEK activity (Marron et al., 2007).
The deletion of both Tie1 and Tek results in a more severe phenotype than the deletions of either Tie1 or Tek alone (Sato et al., 1995; Puri et al., 1999). The deletion of both Tie1 and Angpt1 resulted in impaired development of the right-hand, but not left-hand side venous system in the mouse embryo (Loughna and Sato, 2001).
TIE1 has been implicated as a proinflammatory gene and its silencing in cultured endothelial cells reduced the expression of proinflammatory genes (Chan and Sukhatme, 2009), while TIE1 overexpression upregulated adhesion molecules including VCAM-1, E-selectin and ICAM-1 (Chan et al., 2008).

Homology

H. sapiens: TIE1; M. musculus: Tie1; R. novergicus: Tie1; D. rerio: tie1; X. tropicalis: tie1.

Mutations

Somatic

Somatic missense mutations and synonymous substitutions in TIE1 have been detected in human cancers, but their significance remains to be found out.

Implicated in

Entity name
Various diseases
Note
TIE1 has not been directly shown to be involved in any human diseases. Most of the information concerning Tie1 function has been retrieved from animal models.
Entity name
Gastric cancer
Note
TIE1 expression has been detected in gastric adenocarcinoma tissues where its expression inversely correlated with patients survival (Lin et al., 1999).
Entity name
Atherosclerosis
Note
Tie1 is upregulated in emerging atherosclerotic plaques and around developing aneurysms (Porat et al., 2004), and Tie1+/- mice bred to the ApoE-deficient background displayed a 35% reduction in atherosclerosis relative to Tie1+/+;Apoe-/- mice (Woo et al., 2011).

Bibliography

Pubmed IDLast YearTitleAuthors

Other Information

Locus ID:

NCBI: 7075
MIM: 600222
HGNC: 11809
Ensembl: ENSG00000066056

Variants:

dbSNP: 7075
ClinVar: 7075
TCGA: ENSG00000066056
COSMIC: TIE1

RNA/Proteins

Gene IDTranscript IDUniprot
ENSG00000066056ENST00000372476P35590
ENSG00000066056ENST00000538015P35590

Expression (GTEx)

0
10
20
30
40
50
60

References

Pubmed IDYearTitleCitations
382549612024Cerebrospinal Fluid C1-Esterase Inhibitor and Tie-1 Levels Affect Cognitive Performance: Evidence from Proteome-Wide Mendelian Randomization.0
386175452024TIE1 promotes cervical cancer progression via Basigin-matrix metalloproteinase axis.0
382549612024Cerebrospinal Fluid C1-Esterase Inhibitor and Tie-1 Levels Affect Cognitive Performance: Evidence from Proteome-Wide Mendelian Randomization.0
386175452024TIE1 promotes cervical cancer progression via Basigin-matrix metalloproteinase axis.0
368142842023FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway.4
370962932023Possible biallelic inheritance in TIE1 in a family with congenital lymphedema, intestinal lymphangiectasia and cutis aplasia.0
368142842023FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway.4
370962932023Possible biallelic inheritance in TIE1 in a family with congenital lymphedema, intestinal lymphangiectasia and cutis aplasia.0
349422302022A novel cis-regulatory variant modulating TIE1 expression associated with attention deficit hyperactivity disorder in Han Chinese children.4
349422302022A novel cis-regulatory variant modulating TIE1 expression associated with attention deficit hyperactivity disorder in Han Chinese children.4
338121822021Involvement of small extracellular vesicle-derived TIE-1 in the chemoresistance of ovarian cancer cells.3
338121822021Involvement of small extracellular vesicle-derived TIE-1 in the chemoresistance of ovarian cancer cells.3
329478562020TIE1 as a Candidate Gene for Lymphatic Malformations with or without Lymphedema.7
329478562020TIE1 as a Candidate Gene for Lymphatic Malformations with or without Lymphedema.7
308060322019Metabolic gene NR4A1 as a potential therapeutic target for non-smoking female non-small cell lung cancer patients.7

Citation

Pipsa Saharinen

TIE1 (tyrosine kinase with immunoglobulin-like and EGF-like domains 1)

Atlas Genet Cytogenet Oncol Haematol. 2012-03-01

Online version: http://atlasgeneticsoncology.org/gene/42560/js/lib/tumors-explorer/img/logo-atlas-4.svg